KalVista Pharma Appoints Jeb Ledell As COO

KalVista Pharmaceuticals

8.82 USD 0.80%

• Charts
• News
• Analysen

Kaufen / Verkaufen

(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Monday the appointment of Jeb Ledell as Chief Operating Officer.

Ledell, with more than 20 years of leadership and operational experience in the biotechnology industry, joins from AVEO Oncology, an LG Chem company, where he held the same role and oversaw AVEO's operational strategy.

Prior to AVEO, Ledell served as COO at Enzyvant Therapeutics. He has also held leadership positions at Compass Therapeutics and Horizon Discovery Group.

The appointment comes as KalVista is preparing to launch sebetralstat on a global scale.

Ben Palleiko, Chief Executive Officer of KalVista, said, "I am confident that his proven skills will help us to achieve our goal of delivering sebetralstat to help transform the lives of people living with hereditary angioedema."

In pre-market activity on the Nasdaq, KalVista shares were losing around 1.6 percent to trade at $8.55.